Staff Members - Benha University
Interleukin-37 as an anti-inflammatory cytokine: does its relation to disease activity suggest its potential role in rheumatoid arthritis therapy?
• 2022
Publication Information
Authors
Eman A. Baraka1* , Mona G. Balata2,3, Shereen H. Ahmed4, Afaf F. Khamis5 and Enas A. Elattar2,6
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background: This study aimed to measure the serum and synovial interleukin (IL)-37 levels in rheumatoid arthritis
(RA) patients compared to patients with primary knee osteoarthritis (PKOA) and healthy controls and to detect its
relation to RA disease activity.
Results: This cross-sectional study included 50 RA patients with a mean age of 40.24 ± 8.62 years, 50 patients with
PKOA with a mean age of 56.69 ± 4.21, and 40 healthy controls with a mean age of 41.75 ± 7.38 years. The mean
serum IL-37 level in the RA patients (382.6 ± 73.97 pg/ml) was statistically significantly (P < 0.001) the highest
among the studied groups; however, it showed a non-significant difference between the PKOA patients (70.38 ±
27.49 pg/ml) and the healthy controls (69.97 ± 25.12 pg/ml) (P > 0.94). Both serum and synovial IL-37 levels were
significantly positively correlated with disease activity scores (r = 0.92, P< 0.001 and r = 0.85, P < 0.001), tender joint
counts (r = 0.83, P < 0.001 and r = 0.82, P < 0.001 ), swollen joint counts (r = 0.72, P < 0.001 and r = 0.60, P < 0.001),
visual analog scale (r = 0.82, P < 0.001 and r = 0.82, P < 0.001), erythrocyte sedimentation rate (r = 0.75, P < 0.001
and r = 0.65, P < 0.001), and C-reactive protein (r = 0.93, P < 0.001 and r = 0.79, P < 0.001), respectively.
Conclusion: Serum and synovial IL-37 were significantly elevated in the RA patients, and they were closely
correlated. Being less invasive, the serum IL-37 could be a marker of disease activity and could reflect the effective
disease control by drugs. Having an anti-inflammatory effect could not suggest IL-37 as the key player to control
inflammation alone, but its combination with other anti-proinflammatory cytokines could be investigated.
(RA) patients compared to patients with primary knee osteoarthritis (PKOA) and healthy controls and to detect its
relation to RA disease activity.
Results: This cross-sectional study included 50 RA patients with a mean age of 40.24 ± 8.62 years, 50 patients with
PKOA with a mean age of 56.69 ± 4.21, and 40 healthy controls with a mean age of 41.75 ± 7.38 years. The mean
serum IL-37 level in the RA patients (382.6 ± 73.97 pg/ml) was statistically significantly (P < 0.001) the highest
among the studied groups; however, it showed a non-significant difference between the PKOA patients (70.38 ±
27.49 pg/ml) and the healthy controls (69.97 ± 25.12 pg/ml) (P > 0.94). Both serum and synovial IL-37 levels were
significantly positively correlated with disease activity scores (r = 0.92, P< 0.001 and r = 0.85, P < 0.001), tender joint
counts (r = 0.83, P < 0.001 and r = 0.82, P < 0.001 ), swollen joint counts (r = 0.72, P < 0.001 and r = 0.60, P < 0.001),
visual analog scale (r = 0.82, P < 0.001 and r = 0.82, P < 0.001), erythrocyte sedimentation rate (r = 0.75, P < 0.001
and r = 0.65, P < 0.001), and C-reactive protein (r = 0.93, P < 0.001 and r = 0.79, P < 0.001), respectively.
Conclusion: Serum and synovial IL-37 were significantly elevated in the RA patients, and they were closely
correlated. Being less invasive, the serum IL-37 could be a marker of disease activity and could reflect the effective
disease control by drugs. Having an anti-inflammatory effect could not suggest IL-37 as the key player to control
inflammation alone, but its combination with other anti-proinflammatory cytokines could be investigated.